Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Ny prognose fra Kalundborg Forsyning forudser et vandbehov fra byens stærkt voksende industri, at miljøet er under pres, og ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Det fremgår af det årsregnskab, som Novo Nordisk har aflagt onsdag morgen. Af det store salg landede 100 milliarder på ...

Går Novo Nordisk op i sine medarbejderes ve og vel? Ikke når det kommer til bygningsarbejdere åbenbart. For på trods af sikkerhedsbrister bliver fagforeningen nægtet adgang til at besigtige forholdene ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.